These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 10160102)
41. The role of combination therapy in achieving blood pressure control. Neutel JM Am J Manag Care; 1999 Jun; 5(7 Suppl):S463-8. PubMed ID: 10538855 [No Abstract] [Full Text] [Related]
43. Public health value of fixed-dose combinations in hypertension. Ruilope LM; Burnier M; Muszbek N; Brown RE; Keskinaslan A; Ferber P; Harms G Blood Press Suppl; 2008 Jun; 1():5-14. PubMed ID: 18705530 [TBL] [Abstract][Full Text] [Related]
44. [Analysis of pharmacologic costs in the treatment of arterial hypertension. Approximation to a cost-effectiveness study]. Alonso Moreno FJ; García Palencia M; Laborda Peralta M; Hermoso López A; Lopez de Castro F Aten Primaria; 1998 May; 21(9):607-12. PubMed ID: 9677744 [TBL] [Abstract][Full Text] [Related]
45. [Therapy of hypertension. Cost conscious prevention of complications]. Kolloch RE MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042 [No Abstract] [Full Text] [Related]
46. Economic Evaluation of Pharmacists Tackling the Burden of Hypertension in Japan. Okada H; Johnston K; Nakayama T; Marra C; Tsuyuki RT Hypertension; 2019 Dec; 74(6):e54-e55. PubMed ID: 31607176 [No Abstract] [Full Text] [Related]
47. [The comparative assessment of the efficacy of hypotensive preparations in stage-II hypertension]. Tiurin VP; Fursov AN; Gospodarenko AL; Liapkova NB; Orlov FA Voen Med Zh; 1997 Nov; 318(11):46-7. PubMed ID: 9461836 [No Abstract] [Full Text] [Related]
48. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Paramore LC; Halpern MT; Lapuerta P; Hurley JS; Frost FJ; Fairchild DG; Bates D Am J Manag Care; 2001 Apr; 7(4):389-98. PubMed ID: 11310193 [TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. Ekman M; Bienfait-Beuzon C; Jackson J J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426 [TBL] [Abstract][Full Text] [Related]
50. Role of the Pharmacoeconomic Aspects in the Clinical Management of Hypertension. Degli Esposti L; Degli Esposti E High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):151-4. PubMed ID: 27160719 [TBL] [Abstract][Full Text] [Related]
51. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. Hilleman DE J Manag Care Pharm; 2014 Jan; 20(1):93-100. PubMed ID: 24372463 [No Abstract] [Full Text] [Related]
52. Compliance with antihypertensive therapy: raising the bar of expectations. Rudd P Am J Manag Care; 1998 Jul; 4(7):957-66. PubMed ID: 10181995 [TBL] [Abstract][Full Text] [Related]
53. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial. van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948 [TBL] [Abstract][Full Text] [Related]